Literature DB >> 11763364

Discovery of potent and selective peptide agonists at the GRP-preferring bombesin receptor (BB2).

J G Darker1, S J Brough, J Heath, D Smart.   

Abstract

Analogues of the nonselective bombesin receptor synthetic agonist H-D-Phe-Gln-Trp-Ala-Val-betaAla-His-Phe-Nle-NH2 were prepared and their biological activity assessed at the NMB-preferring/bombesin receptor (NMB-R: BB1), the GRP-preferring/bombesin receptor (GRP-R: BB2) and the orphan receptor bombesin receptor subtype-3 (BRS-3; BB3). Progressive N-terminal deletions identified the minimum C-terminal sequences required for maintaining a significant agonist effect, whilst an alanine scan, targeted changes in stereochemistry and other pertinent substitutions identified key side-chain and stereochemical requirements for activation. Key structural elements required for functional potency at BB1 BB2 and BB3, and for selectivity between these receptor subtypes were established. Synthetic peptides were discovered. which were highly potent agonists at BB2 and extremely selective over both BB1 and BB3.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11763364     DOI: 10.1002/psc.359

Source DB:  PubMed          Journal:  J Pept Sci        ISSN: 1075-2617            Impact factor:   1.905


  2 in total

1.  Design, synthesis, and biological evaluation of an antagonist-bombesin analogue as targeting vector.

Authors:  Wael R Abd-Elgaliel; Fabio Gallazzi; Jered C Garrison; Tammy L Rold; Gary L Sieckman; Said Daibes Figueroa; Timothy J Hoffman; Susan Z Lever
Journal:  Bioconjug Chem       Date:  2008-09-23       Impact factor: 4.774

Review 2.  Peptide-Drug Conjugates and Their Targets in Advanced Cancer Therapies.

Authors:  Paul Hoppenz; Sylvia Els-Heindl; Annette G Beck-Sickinger
Journal:  Front Chem       Date:  2020-07-07       Impact factor: 5.221

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.